The Best Research Peptides
for Fat Loss in 2026
Three GLP-class compounds ranked by peer-reviewed Phase 2 and Phase 3 clinical trial weight loss outcomes — not anecdote. Retatrutide leads at 24.2%, Tirzepatide follows at 22.5%, Semaglutide benchmarks at 14.9%.
Fat Loss Peptides — Ranked #1 to #3
Ordered by mean weight loss % in pivotal clinical trials
Retatrutide
TRIPLE AGONISTTOP PICKGLP-1 + GIP + Glucagon receptor agonist
- Activates three distinct metabolic receptors simultaneously
- Glucagon receptor agonism drives direct adipose lipolysis
- Fastest rate of weight loss in clinical trials to week 48
- Phase 2 data: 24.2% mean weight reduction at 48 weeks (12 mg cohort)
- Phase 3 trials (TRIUMPH program) ongoing as of 2026
Tirzepatide
DUAL AGONISTGLP-1 + GIP dual receptor agonist
- FDA-approved dual GLP-1/GIP agonist (Mounjaro / Zepbound)
- SURMOUNT-1: 22.5% mean weight loss at 72 weeks (15 mg cohort)
- Largest controlled trial dataset of any GLP-class compound
- GIP receptor adds insulin-sensitizing effect on top of GLP-1
- Strong safety and tolerability profile from Phase 3 data
Semaglutide
GLP-1 AGONISTGLP-1 receptor agonist (single target)
- First-generation GLP-1 receptor agonist at scale
- STEP-1: 14.9% mean weight loss at 68 weeks (2.4 mg cohort)
- FDA-approved (Wegovy) with the most post-market data
- Pure GLP-1 mechanism: appetite suppression + gastric slowing
- Lowest cost per dose among the three; widest research literature
Side-by-Side Comparison
| Metric | Retatrutide ★ | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor Targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 |
| Trial Weight Loss | −24.2% (48 wk) | −22.5% (72 wk) | −14.9% (68 wk) |
| Trial Name | Phase 2 NEJM 2023 | SURMOUNT-1 | STEP-1 |
| Research Dose (Max) | 12 mg/week | 15 mg/week | 2.4 mg/week |
| Direct Lipolysis | Yes (glucagon agonism) | Indirect only | Indirect only |
| Approval Status | Phase 3 ongoing | FDA approved | FDA approved |
| Relative Cost | $$$ | $$ | $ |
Weight loss percentages are mean values from pivotal Phase 2/3 trials at highest studied doses. For research reference only.
Retatrutide — The Triple-Agonist
Retatrutide (LY3437943) is a once-weekly synthetic peptide that simultaneously activates three metabolic receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-receptor mechanism is why it consistently outperforms every other compound in its class on raw weight loss outcomes.
The GLP-1 component reduces appetite by acting on hypothalamic satiety neurons and slows gastric emptying, creating prolonged fullness. The GIP component enhances glucose-dependent insulin secretion and improves adipose insulin sensitivity. The glucagon receptor agonism — absent in tirzepatide and semaglutide — drives direct lipolysis in adipocytes and increases hepatic fat oxidation, meaning the body is actively burning stored fat rather than simply eating less.
In the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving 12 mg weekly for 48 weeks achieved a mean body weight reduction of 24.2% — the highest figure recorded for any GLP-class compound at that time. Phase 3 trials under the TRIUMPH program are ongoing.
Tirzepatide — The Dual Agonist
Tirzepatide (LY3298176) is a dual GLP-1/GIP agonist approved by the FDA under the brand names Mounjaro (T2D) and Zepbound (obesity). It was the first compound to achieve greater than 20% mean weight loss in a randomized controlled trial — a milestone reached in the SURMOUNT-1 study (Jastreboff et al., NEJM 2022), where participants on 15 mg/week for 72 weeks lost a mean of 22.5% of baseline body weight.
The addition of GIP receptor agonism to GLP-1 agonism produces a synergistic effect on insulin sensitivity and appetite regulation. GIP receptors are expressed in adipose tissue, and their activation appears to improve the responsiveness of fat cells to insulin, reducing ectopic fat deposition. SURMOUNT-1 also demonstrated that tirzepatide subjects lost disproportionately more fat mass (as measured by DEXA) relative to lean mass — a favorable body composition outcome for research into cutting protocols.
Tirzepatide holds the deepest clinical evidence base of any GLP-class compound currently available, with multiple Phase 3 trials completed across obesity, T2D, heart failure, and sleep apnea indications.
Semaglutide — The GLP-1 Benchmark
Semaglutide is a selective GLP-1 receptor agonist that established GLP-class compounds as a serious fat loss research category. The STEP-1 trial (Wilding et al., NEJM 2021) demonstrated a mean weight loss of 14.9% at 68 weeks with subcutaneous 2.4 mg/week dosing — a figure that dramatically exceeded expectations for a single-receptor compound.
Semaglutide works by mimicking endogenous GLP-1 with a half-life extended to approximately seven days via a C18 fatty diacid side-chain modification, enabling once-weekly dosing. Its mechanism is purely GLP-1 mediated: hypothalamic appetite suppression, delayed gastric emptying, and improved glucose-dependent insulin secretion. Without the GIP or glucagon receptor components of the higher-ranked compounds, it lacks direct lipolytic stimulation — explaining the roughly 7–9% gap in trial weight loss versus tirzepatide.
As the lowest-cost entry point in this class and the compound with the most extensive real-world safety data, semaglutide remains an important research benchmark and a valid entry compound for GLP-1 mechanism studies.
The Clavicular Protocol
How Clavicular combines these compounds into a complete fat loss and body recomposition stack — not just a single peptide.
Lead with the triple agonist
Retatrutide anchors the protocol as the primary fat loss driver. The GLP-1 component manages appetite, GIP improves insulin dynamics, and the glucagon receptor drives active fat oxidation around the clock — not just at meals.
Layer a GH secretagogue
A CJC-1295/Ipamorelin blend or similar growth hormone secretagogue is added to support lean mass preservation during aggressive caloric restriction. The pulsatile GH response helps counteract the muscle-sparing challenge of rapid weight loss.
Support skin & connective tissue
Rapid fat loss can leave connective tissue lagging. GLOW (GHK-Cu) is added to support collagen remodeling and skin elasticity — the looksmax component that separates a Clavicular-style protocol from a bare-minimum GLP cut.
Source research grade only
Purity and peptide integrity determine results. Lyophilized powder with >98% HPLC-verified purity from a traceable supplier is the baseline requirement. Our trusted research supplier — Clav Tides — meets that bar.
The Clavicular Stack — Built Around Retatrutide
Retatrutide 15mg + GLOW (GHK-Cu). The exact combination behind the viral transformation — triple-agonist fat loss with skin and connective tissue support.
Frequently Asked Questions
What is the best peptide for fat loss?
Based on Phase 2 clinical data, Retatrutide is the top-performing fat loss peptide, demonstrating a mean weight reduction of 24.2% in a 48-week trial at the 12 mg dose (NEJM, 2023). Its triple-receptor mechanism targeting GLP-1, GIP, and glucagon receptors simultaneously produces superior fat oxidation compared to single or dual agonists.
How do fat loss peptides work?
GLP-1 receptor agonist peptides reduce appetite by acting on hypothalamic satiety centers, slow gastric emptying to prolong fullness, and improve insulin sensitivity to reduce fat storage. Dual agonists (GLP-1/GIP) add GIP-mediated enhancement of insulin secretion. Triple agonists like Retatrutide further add glucagon receptor activation, which directly stimulates fat oxidation in adipose tissue.
Which peptide burns fat fastest?
Research trials show Retatrutide achieves the fastest rate of weight loss due to its triple agonism (GLP-1 + GIP + Glucagon). The glucagon receptor component specifically drives direct lipolysis and fatty acid oxidation in addition to the appetite suppression shared by all GLP-class compounds. Phase 2 data shows subjects reaching ~17% weight loss by week 24 — a pace not matched by tirzepatide or semaglutide in comparable trials.
Are fat loss peptides safe?
All products listed on this site are for laboratory research only and are not intended for human consumption, injection, or ingestion. The clinical trial data referenced is from controlled pharmaceutical studies. This page is for informational and research reference purposes only. Consult a licensed healthcare professional before considering any peptide-based protocol.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual GLP-1/GIP agonist that targets two receptors. Retatrutide is a triple agonist that adds glucagon receptor activation on top of GLP-1 and GIP. The extra glucagon receptor engagement drives direct fat oxidation, which is why Phase 2 data shows Retatrutide outperforming Tirzepatide (24.2% vs 22.5% mean weight loss) over comparable trial durations.
Can peptides help with cutting while preserving muscle?
GLP-class peptides primarily drive weight loss through caloric restriction mechanisms (appetite suppression, delayed gastric emptying). Research in the SURMOUNT trials showed that tirzepatide subjects lost proportionally more fat mass than lean mass. Retatrutide's glucagon component may provide additional lipolytic benefit. For muscle preservation during a cut, researchers often pair GLP-class compounds with GH secretagogues like CJC-1295/Ipamorelin.
Source the #1 Fat Loss Peptide
Retatrutide — triple-agonist, 24.2% trial weight loss — available as research-grade lyophilized powder from our trusted supplier. >98% purity, free shipping on orders over $200.
For laboratory research purposes only. Not for human consumption.